Literature DB >> 15499210

Molecular aetiology of primary hyperoxaluria type 1.

Christopher J Danpure1.   

Abstract

Primary hyperoxaluria type 1 (PH1) is a rare autosomal-recessive disorder, caused by a deficiency of the liver-specific intermediary-metabolic enzyme alanine:glyoxylate aminotransferase (AGT). AGT deficiency results in increased synthesis and excretion of the metabolic end-product oxalate and the deposition of insoluble calcium oxalate in the kidney and urinary tract. Numerous mutations and polymorphisms have been identified in the gene (AGXT) that encodes AGT, some of which interact synergistically to cause a variety of complex enzyme phenotypes, including AGT intraperoxisomal aggregation, accelerated degradation, and peroxisome-to-mitochondrion mistargeting. The latter is the single most common cause of PH1 and results from the functional interaction between a common Pro11Leu polymorphism and a disease-specific Gly170Arg mutation. The recent solution of the crystal structure of AGT has enabled the effects of several mutations and polymorphisms to be rationalised in terms of their likely effects on AGT conformation. Increased understanding of the molecular aetiology of PH1 has led to significant improvements in all aspects of the clinical management of the disorder, including diagnosis (by enzyme assay of percutaneous needle liver biopsies), prenatal diagnosis (by DNA analysis of chorionic villus samples) and treatment (by liver transplantation as a form of enzyme replacement therapy). Copyright (c) 2004 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15499210     DOI: 10.1159/000080254

Source DB:  PubMed          Journal:  Nephron Exp Nephrol        ISSN: 1660-2129


  14 in total

Review 1.  Primary hyperoxaluria type 1: is genotyping clinically helpful?

Authors:  Ernst Leumann; Bernd Hoppe
Journal:  Pediatr Nephrol       Date:  2005-03-17       Impact factor: 3.714

2.  Phenotype-Genotype Correlations and Estimated Carrier Frequencies of Primary Hyperoxaluria.

Authors:  Katharina Hopp; Andrea G Cogal; Eric J Bergstralh; Barbara M Seide; Julie B Olson; Alicia M Meek; John C Lieske; Dawn S Milliner; Peter C Harris
Journal:  J Am Soc Nephrol       Date:  2015-02-02       Impact factor: 10.121

Review 3.  Primary hyperoxaluria type 1: still challenging!

Authors:  Pierre Cochat; Aurélia Liutkus; Sonia Fargue; Odile Basmaison; Bruno Ranchin; Marie-Odile Rolland
Journal:  Pediatr Nephrol       Date:  2006-06-30       Impact factor: 3.714

Review 4.  An update on primary hyperoxaluria.

Authors:  Bernd Hoppe
Journal:  Nat Rev Nephrol       Date:  2012-06-12       Impact factor: 28.314

5.  Correlation between the molecular effects of mutations at the dimer interface of alanine-glyoxylate aminotransferase leading to primary hyperoxaluria type I and the cellular response to vitamin B6.

Authors:  Mirco Dindo; Elisa Oppici; Daniele Dell'Orco; Rosa Montone; Barbara Cellini
Journal:  J Inherit Metab Dis       Date:  2017-11-06       Impact factor: 4.982

Review 6.  The primary hyperoxalurias.

Authors:  Bernd Hoppe; Bodo B Beck; Dawn S Milliner
Journal:  Kidney Int       Date:  2009-02-18       Impact factor: 10.612

7.  Epigenetic profiles of pre-diabetes transitioning to type 2 diabetes and nephropathy.

Authors:  Thomas A VanderJagt; Monica H Neugebauer; Marilee Morgan; Donald W Bowden; Vallabh O Shah
Journal:  World J Diabetes       Date:  2015-08-10

Review 8.  The renal biopsy in the genomic era.

Authors:  Helen Liapis; Joseph P Gaut
Journal:  Pediatr Nephrol       Date:  2012-11-21       Impact factor: 3.714

9.  Molecular requirements for peroxisomal targeting of alanine-glyoxylate aminotransferase as an essential determinant in primary hyperoxaluria type 1.

Authors:  Krisztián Fodor; Janina Wolf; Ralf Erdmann; Wolfgang Schliebs; Matthias Wilmanns
Journal:  PLoS Biol       Date:  2012-04-17       Impact factor: 8.029

10.  Intra-operative continuous renal replacement therapy during combined liver-kidney transplantation in two patients with primary hyperoxaluria type 1.

Authors:  Casper F M Franssen; Ido P Kema; Douglas J Eleveld; Robert J Porte; Jaap J Homan van der Heide
Journal:  NDT Plus       Date:  2011-02-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.